Abstract: Syndecan binding protein (SDCBP) has been identified as a molecule linking syndecan-mediated signaling to the cyto -skeleton; SDCBP has also contributed to the development of many malignancies, including breast cancer. Breast cancer is a heteroge -neous disease encompassing multiple subgroups with different molecular signatures, clinical characteristics, and responses to therapies. This article reviews the pathways of SDCBP interaction and its functions in the tumor progression of breast cancer and other malignan-cies to provide novel ideas of targeted therapies for breast cancers, particularly triple- negative and endocrine therapy- resistant breast cancers and other malignancies, that lack effective individualized treatments.